Fast Melt Tablets Market Size and Trends

The Global Fast Melt Tablets Market is estimated to be valued at USD 6.20 Bn in 2025 and is expected to reach USD 11.41 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.1% from 2025 to 2032.

Key Takeaways of the Fast Melt Tablets Market:

In terms of type, the anti psychotics segment is expected to contribute the highest share of the market with 22.1% in 2025.
In terms of indication, the pain management segment is expected to contribute the highest share of the market with 34.2% in 2025.
By dosage form, the oral segment is expected to contribute the highest share of the market with 42.1% in 2025.
North America is expected to top the global market with 36.5% share in 2025, followed by Asia Pacific with 27.7% share in 2025.

Market Overview:

Factors such as increasing preference for convenient dosage forms among geriatric and pediatric population, growing awareness about fast dissolving tablets, and rising prevalence of various diseases are expected to drive the market growth. The demand for fast dissolving tablets is increasing majorly from developed regions like North America and Europe owing to growing healthcare expenditure and high per capita income in these regions. However, improving healthcare infrastructure and increasing healthcare spending in emerging markets like Asia Pacific and Latin America are expected to offer lucrative opportunities for the growth of the fast melt tablets market in the coming years.

Fast Melt Tablets Market Concentration By Players

To learn more about this report, Request sample copy

Key Developments:

In December 2022, Melt Pharmaceuticals, Inc., a clinical-stage company, announced Phase 2 results for MELT-300, its lead product for needle- and opioid-free procedural sedation during cataract surgery. MELT-300 is a sublingual tablet combining midazolam (3mg) and ketamine (50mg) using Catalent's Zydis fast-dissolving technology for rapid absorption. The double-blind, placebo-controlled study enrolled over 300 subjects at nine sites to evaluate its efficacy and safety compared to placebo and individual components.
Fuji Chemical Industries Co., Ltd.’sv F-MELT is a proprietary excipient designed for producing Fast Melt Tablets (FMTs) and chewable tablets. Ideal for orally disintegrating tablets (ODTs), it enables rapid disintegration in the mouth without water, enhancing patient convenience and compliance. F-MELT supports direct compressibility, allowing easy blending with active pharmaceutical ingredients (APIs) for efficient manufacturing. Its versatility and patient-friendly features make it a leading choice for innovative tablet formulations.

Top Strategies Followed by Global Fast Melt Tablets Market Players

Leading pharmaceutical companies are heavily investing in R&D to innovate high-performance Fast Melt Tablets (FMTs)
- For instance, SPI Pharma has developed proprietary excipients like PharmaBurst 500, Mannogem XL Opal, and Mannogem XL Ruby, which are tailored for orally disintegrating tablets (ODTs), fast-melt, and chewable formulations. These excipients enable rapid disintegration within 30 seconds, enhancing patient compliance and satisfaction.
Mid-level players adopt cost-effective strategies to reach price-sensitive groups. Collaborations help strengthen product pipelines and distribution networks. Strategic alliances are crucial for established players to solidify their market presence.
- For example, forming alliances with major industry players and Original Equipment Manufacturers (OEMs) is a common strategy to solidify market presence. For example, Emisphere Technologies collaborated with a nationally deployed field force and retail pharmacies to launch Eligen B12, the first oral prescription tablet for vitamin B12 deficiency.
Emerging manufacturers specialize in niche segments. Expanding global distribution networks is crucial for enhancing market reach. Companies like Rentschler Biopharma have demonstrated this by leveraging their dual-site capabilities across the United States and Europe. This strategic expansion allows them to support a range from clinical development to commercial-scale manufacturing, offering versatile production capacities and meeting diverse market demands

Emerging Startups - Fast Melt Tablets Industry Ecosystem

Startups like Melt Pharmaceuticals are developing advanced technologies including smart sensors for monitoring drug delivery. Their innovative approach is expected to significantly influence market dynamics by improving patient adherence and treatment outcomes
Startups are focusing on sustainability by developing eco-friendly products and utilizing recycled materials. While specific examples in the FMT sector are limited, the broader pharmaceutical industry is increasingly adopting sustainable practices, such as using biodegradable excipients and reducing carbon footprints in manufacturing processes.
Emerging startups are addressing niche markets by developing FMTs for specific therapeutic areas, such as pediatric or geriatric formulations. For example, SPI Pharma's Mannogem XL Opal is designed for fast-melt and chewable tablets, catering to the needs of patients who have difficulty swallowing traditional tablets.